search

Active clinical trials for "Poliomyelitis"

Results 171-180 of 207

Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand

DiphtheriaTetanus3 more

The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 2, 4, and 6 months of age followed by a booster dose during the second year of life and concomitant hepatitis B vaccine at 2 and 6 months of age in infants in Thailand.

Completed14 enrollment criteria

Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China

Poliomyelitis

This study aims to obtain the direct domestic IPV vaccine monitoring data for the CNBG products, and provide scientific evidence for the National Immunization Program and long-term polio vaccine immunization policy. The overall objective of this research is to determine the seroconversion rates of two reduced Sabin IPV schedules in Chinese children - a 2-dose schedule and a 3-dose schedule.

Completed5 enrollment criteria

Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh

Polio

Hypothesis: The immunogenicity of oral polio vaccine (OPV) will be enhanced in Bangladeshi infants who receive bicarbonate buffer at the time of polio immunization.

Completed8 enrollment criteria

Safety of Imovax Polio in Chinese Infants and Children

Poliomyelitis

To describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions (injection site and systemic) within eight days after one dose of IMOVAX Polio™ administered in children and infants.

Completed17 enrollment criteria

Immunogenicity and Safety of Pentaxim in South African Infants

DiphtheriaTetanus3 more

The present clinical study will assess the immunogenicity and reactogenicity of Aventis Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 6, 10 and 14 weeks of age followed by a booster dose during the second year of life in order to meet the requirements for application for the use of the product in the Expanded Program on Immunization (EPI) in South Africa.

Completed18 enrollment criteria

Immunogenicity and Safety of Adacel Polio Vaccine

DiphtheriaTetanus2 more

The present study is designed to meet the requirements of the Taiwanese Health Authorities for registration of ADACEL POLIO in Taiwan. Subjects will receive one dose of the study vaccine at 6 to 8 years of age. Blood samples will be taken for antibody titration. The expected total duration of follow-up for each subject will be 28 days.

Completed21 enrollment criteria

Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants...

PoliomyelitisTetanus3 more

This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa, IPV, hepatitis B, Hib and Men C vaccines during the first year of life.

Completed8 enrollment criteria

A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.

Poliomyelitis

In April 2017, WHO recommended that a two-dose, Inactivated Poliovirus Vaccine, IPV-only schedule at 4 months and 8 months of age can be used after polio eradication, with a schedule seroconversion target of at least 90%. However, there is no such data for China domestic Sabin strain IPVs to support a 2-dose schedule among Chinese infants. This research is to determine the seroconversion rates among two arms: Group 1: two-dose schedule, infants will be received two doses of Sabin IPV, the first dose at 4 month of age, and the second dose at 8-11 month of age. Group 2: three-dose schedule, infants will be received three doses of Sabin IPV at 2, 3 and 4 month of age respectively. This schedule is currently recommended by manufacture's package insert for routine use. The hypothesis is the seroconversion will be above 90% in both groups.

Completed5 enrollment criteria

Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus...

Poliomyelitis

This study is a supplementary study of an already finished randomised, double-blinded, and placebo controlled phase 2 clinical trial of an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd., Beijing China. The purpose of this study is to evaluate the cross-neutralization capacity of the serum immuned by the investigational sIPV against 10 individual virus strains.

Completed4 enrollment criteria

Duration of IPV Priming and Antibody Decay

Poliomyelitis

This is an open-label randomized phase IV clinical trial assessing immunogenicity of poliovirus vaccines.Participants will be enrolled at 6 weeks of age and followed to 18 months of age. The study will recruit 1645 participants in five arms.

Completed13 enrollment criteria
1...171819...21

Need Help? Contact our team!


We'll reach out to this number within 24 hrs